Immunovative develops products which integrate with novel protocols to stimulate a cascade of immune events in a patient to elicit the Mirror EffectTM mechanism.  By developing products as immune tools and then integrating the products into steps of a protocol, we can accomplish unprecedented control of the immune system.  This control can be realized even in heavily pre-treated, high tumor burdened, metastatic cancer patients or patients suffering from incurable infectious diseases (such as HIV, hepatitis, herpes, ebola, malaria, etc).  Patients at this late stage of disease were previously thought to have been poor candidates for immunotherapy.  With a single product delivered by different routes at different times, strategically planned into a protocol, we can train the immune system to identify cancer or viral infected cells, create and effective immune response and imprint this response over the resident failed response and disable the ability of the cancer or virus to evade immune attack. 



Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more